Joshua J Gagne

List of Publications by Year
in descending order

200 papers	5,104 citations	136950 32 h-index	123424 61 g-index
204 all docs	204 docs citations	204 times ranked	6280 citing authors

#	Article	IF	Citations
1	A combined comorbidity score predicted mortality in elderly patients better than existing scores. Journal of Clinical Epidemiology, 2011, 64, 749-759.	5.0	728
2	Development of a Comorbidity Index for Use in Obstetric Patients. Obstetrics and Gynecology, 2013, 122, 957-965.	2.4	325
3	Effects of Adjusting for Instrumental Variables on Bias and Precision of Effect Estimates. American Journal of Epidemiology, 2011, 174, 1213-1222.	3.4	205
4	Seizure Outcomes Following the Use of Generic versus Brand-Name Antiepileptic Drugs. Drugs, 2010, 70, 605-621.	10.9	164
5	Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes. Annals of Internal Medicine, 2014, 161, 400.	3.9	137
6	Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 480-486.	2.2	128
7	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Pharmacoepidemiology and Drug Safety, 2017, 26, 1018-1032.	1.9	126
8	Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. European Journal of Clinical Pharmacology, 2008, 64, 1125-1132.	1.9	108
9	Association of Opioid Overdose With Opioid Prescriptions to Family Members. JAMA Internal Medicine, 2019, 179, 1186.	5.1	72
10	Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice. Annals of Internal Medicine, 2020, 172, 463.	3.9	72
11	Effect of a Remotely Delivered Tailored Multicomponent Approach to Enhance Medication Taking for Patients With Hyperlipidemia, Hypertension, and Diabetes. JAMA Internal Medicine, 2018, 178, 1182.	5.1	71
12	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Value in Health, 2017, 20, 1009-1022.	0.3	70
13	Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Medical Care, 2017, 55, 1046-1051.	2.4	67
14	Estimation using all available covariate information versus a fixed look‑back window for dichotomous covariates. Pharmacoepidemiology and Drug Safety, 2013, 22, 542-550.	1.9	66
15	Availability of Comparative Efficacy Data at the Time of Drug Approval in the United States. JAMA - Journal of the American Medical Association, 2011, 305, 1786.	7.4	62
16	How Many â€œMe-Tooâ€•Drugs Is Too Many?. JAMA - Journal of the American Medical Association, 2011, 305, 711.	7.4	61
17	Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses. American Journal of Epidemiology, 2018, 187, 1799-1807.	3.4	56
18	Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLoS Medicine, 2019, 16, e1002763.	8.4	55

#	Article	IF	Citations
19	Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey. Journal of General Internal Medicine, 2016, 31, 609-614.	2.6	53
20	Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis. JAMA Dermatology, 2019, 155, 1142.	4.1	51
21	Association of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection. JAMA Internal Medicine, 2020, 180, 1596.	5.1	48
22	Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation. Annals of Internal Medicine, 2021, 174, 1214-1223.	3.9	48
23	Confounder summary scores when comparing the effects of multiple drug exposures. Pharmacoepidemiology and Drug Safety, 2010, 19, 2-9.	1.9	47
24	Disease risk score as a confounder summary method: systematic review and recommendations. Pharmacoepidemiology and Drug Safety, 2013, 22, 122-129.	1.9	44
25	Prevalence and Predictors of Generic Drug Skepticism Among Physicians. JAMA Internal Medicine, 2016, 176, 845.	5.1	43
26	Medication Synchronization Programs Improve Adherence To Cardiovascular Medications And Health Care Use. Health Affairs, 2018, 37, 125-133.	5.2	41
27	Measuring drug exposure: concordance between defined daily dose andÂdays' supply depended on drug class. Journal of Clinical Epidemiology, 2016, 69, 107-113.	5.0	40
28	Confounding of the association between statins and Parkinson disease: systematic review and metaâ€analysis. Pharmacoepidemiology and Drug Safety, 2017, 26, 294-300.	1.9	39
29	Comparative effectiveness of generic versus brand-name antiepileptic medications. Epilepsy and Behavior, 2015, 52, 14-18.	1.7	38
30	Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice. Annals of Internal Medicine, 2017, 167, 845.	3.9	37
31	Opioid Overdose After Surgical Discharge. JAMA - Journal of the American Medical Association, 2018, 320, 502.	7.4	37
32	Control yourself: <scp>ISPEâ€endorsed</scp> guidance in the application of <scp>selfâ€controlled</scp> study designs in pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 2021, 30, 671-684.	1.9	36
33	Switching generic antiepileptic drug manufacturer not linked to seizures. Neurology, 2016, 87, 1796-1801.	1.1	35
34	Data Mining for Adverse Drug Events With a Propensity Score-matched Tree-based Scan Statistic. Epidemiology, 2018, 29, 895-903.	2.7	34
35	Comparative Effectiveness of Preventative Therapy for Venous Thromboembolism After Coronary Artery Bypass Graft Surgery. Circulation: Cardiovascular Interventions, 2012, 5, 590-596.	3.9	32
36	Effect of Generic Competition on Atorvastatin Prescribing and Patientsâ€™ Out-of-Pocket Spending. JAMA Internal Medicine, 2016, 176, 1317.	5.1	32

#	Article	IF	Citations
37	Sentinel Modular Program for Propensity Score–Matched Cohort Analyses. Epidemiology, 2017, 28, 838-846.	2.7	32
38	Thiazolidinediones and Parkinson Disease: A Cohort Study. American Journal of Epidemiology, 2015, 182, 936-944.	3.4	31
39	Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2019, 321, 374.	7.4	31
40	Patterns of opioid initiation at first visits for pain in United States primary care settings. Pharmacoepidemiology and Drug Safety, 2018, 27, 495-503.	1.9	30
41	Impact of High Deductible Health Plans on Cardiovascular Medication Adherence and Health Disparities. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004632.	2.2	30
42	Identification of Associations Between Prescribed Medications and Cancer: A Nationwide Screening Study. EBioMedicine, 2016, 7, 73-79.	6.1	29
43	Using Previous Medication Adherence to Predict Future Adherence. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 1146-1155.	0.9	29
44	Treatment Dynamics of Newly Marketed Drugs and Implications for Comparative Effectiveness Research. Value in Health, 2013, 16, 1054-1062.	0.3	28
45	Patients' Preferences in Anticoagulant Therapy. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 912-919.	2.2	28
46	Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study. European Journal of Cancer, 2017, 70, 22-33.	2.8	28
47	Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta‐analysis of epidemiologic studies. Pharmacoepidemiology and Drug Safety, 2009, 18, 259-268.	1.9	27
48	Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. BMJ: British Medical Journal, 2018, 361, k1180.	2.3	27
49	Hypothesis-free screening of large administrative databases for unsuspected drug-outcome associations. European Journal of Epidemiology, 2018, 33, 545-555.	5.7	27
50	Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia. Diabetes Care, 2018, 41, 713-722.	8.6	26
51	Drug utilization patterns and adherence in patients on systemic medications for the treatment of psoriasis: A retrospective, comparative cohort study. Journal of the American Academy of Dermatology, 2018, 79, 1061-1068.e1.	1.2	26
52	Candidemia in the in-patient setting: treatment options and economics. Expert Opinion on Pharmacotherapy, 2007, 8, 1643-1650.	1.8	25
53	Rationale and design of the Study of a Tele-pharmacy Intervention for Chronic diseases to Improve Treatment adherence (STIC2IT): A cluster-randomized pragmatic trial. American Heart Journal, 2016, 180, 90-97.	2.7	24
54	Performance of Disease Risk Score Matching in Nested Case-Control Studies: A Simulation Study. American Journal of Epidemiology, 2016, 183, 949-957.	3.4	24

#	Article	IF	Citations
55	Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity. Drugs, 2020, 80, 1961-1972.	10.9	24
56	Case-crossover Studies of Therapeutics. Epidemiology, 2013, 24, 375-378.	2.7	23
57	Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study. American Heart Journal, 2021, 233, 109-121.	2.7	23
58	Daysâ€™ Supply of Initial Opioid Analgesic Prescriptions and Additional Fills for Acute Pain Conditions Treated in the Primary Care Setting â€" United States, 2014. Morbidity and Mortality Weekly Report, 2019, 68, 140-143.	15.1	23
59	Use of olmesartan and enteropathy outcomes: a multiâ€database study. Alimentary Pharmacology and Therapeutics, 2018, 47, 792-800.	3.7	22
60	Using Realâ€World Data to Extrapolate Evidence From Randomized Controlled Trials. Clinical Pharmacology and Therapeutics, 2019, 105, 1156-1163.	4.7	22
61	A modular, prospective, semiâ€automated drug safety monitoring system for use in a distributed data environment. Pharmacoepidemiology and Drug Safety, 2014, 23, 619-627.	1.9	21
62	Comparison of high-dimensional confounder summary scores in comparative studies of newly marketed medications. Journal of Clinical Epidemiology, 2016, 76, 200-208.	5.0	21
63	Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics. International Journal of Cardiology, 2017, 228, 761-770.	1.7	21
64	Impact of an Interaction Between Clopidogrel and Selective Serotonin Reuptake Inhibitors. American Journal of Cardiology, 2017, 119, 651-657.	1.6	21
65	Trends in Opioid Prescription in Children and Adolescents in a Commercially Insured Population in the United States, 2004-2017. JAMA Pediatrics, 2019, 173, 98.	6.2	21
66	A National Population-based Study of Adults With Coronary Artery Disease and Coarctation of the Aorta. American Journal of Cardiology, 2018, 122, 2120-2124.	1.6	20
67	Patterns and Predictors of Generic Narrow Therapeutic Index Drug Use Among Older Adults. Journal of the American Geriatrics Society, 2013, 61, 1586-1591.	2.6	19
68	Ensuring Patient Privacy in Data Sharing for Postapproval Research. New England Journal of Medicine, 2014, 371, 1644-1649.	27.0	19
69	Validation of the Combined Comorbidity Index of Charlson and Elixhauser to Predict 30-Day Mortality Across ICD-9 and ICD-10. Medical Care, 2018, 56, 812-812.	2.4	19
70	"First-Wave" Bias When Conducting Active Safety Monitoring of Newly Marketed Medications with Outcome-Indexed Self-Controlled Designs. American Journal of Epidemiology, 2014, 180, 636-644.	3.4	18
71	Estimating Rebates and Other Discounts Received by Medicare Part D. JAMA Health Forum, 2021, 2, e210626.	2.2	18
72	Statins and colorectal cancer risk: a longitudinal study. Cancer Causes and Control, 2013, 24, 777-782.	1.8	17

#	Article	IF	Citations
73	Dimension reduction and shrinkage methods for high dimensional disease risk scores in historical data. Emerging Themes in Epidemiology, 2016, 13, 5.	2.7	17
74	A Case–Crossover–Based Screening Approach to Identifying Clinically Relevant Drug–Drug Interactions in Electronic Healthcare Data. Clinical Pharmacology and Therapeutics, 2019, 106, 238-244.	4.7	17
75	A Unified Framework for Classification of Methods for Benefit-Risk Assessment. Value in Health, 2015, 18, 250-259.	0.3	16
76	Clinical Outcomes of Concomitant Use of Warfarin and Selective Serotonin Reuptake Inhibitors. Journal of Clinical Psychopharmacology, 2017, 37, 200-209.	1.4	16
77	Development and Application of Two Semi-Automated Tools for Targeted Medical Product Surveillance in a Distributed Data Network. Current Epidemiology Reports, 2017, 4, 298-306.	2.4	16
78	Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System. Pharmacoepidemiology and Drug Safety, 2018, 27, 263-271.	1.9	16
79	The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety. Cardiovascular Diabetology, 2020, 19, 25.	6.8	16
80	Coprescription of Opioids With Other Medications and Risk of Opioid Overdose. Clinical Pharmacology and Therapeutics, 2021, 110, 1011-1017.	4.7	16
81	Near-Real-Time Monitoring of New Drugs: An Application Comparing Prasugrel Versus Clopidogrel. Drug Safety, 2014, 37, 151-161.	3.2	15
82	Pharmacoepidemiological assessment of drug interactions with vitamin K antagonists. Pharmacoepidemiology and Drug Safety, 2014, 23, 1160-1167.	1.9	15
83	A review of the performance of different methods for propensity score matched subgroup analyses and a summary of their application in peer-reviewed research studies. Pharmacoepidemiology and Drug Safety, 2017, 26, 1507-1512.	1.9	15
84	The "Dry-Run" Analysis: A Method for Evaluating Risk Scores for Confounding Control. American Journal of Epidemiology, 2017, 185, 842-852.	3.4	15
85	Generating Evidence of Clinical Outcomes of Drug–Drug Interactions. Drug Safety, 2017, 40, 101-103.	3.2	14
86	Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study. Diabetes, Obesity and Metabolism, 2019, 21, 1037-1042.	4.4	14
87	Validation of a comorbidity index for use in obstetric patients: A nationwide cohort study. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 399-405.	2.8	14
88	Rates and Costs of Dispensing Naloxone to Patients at High Risk for Opioid Overdose in the United States, 2014–2018. Drug Safety, 2020, 43, 669-675.	3.2	14
89	Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2022, 327, 1051.	7.4	14
90	Impact of Topiramate Migraine Prophylaxis on Workplace Productivity: Results from Two US Randomized, Double-Blind, Placebo-Controlled, Multicenter Trials. Journal of Occupational and Environmental Medicine, 2007, 49, 252-257.	1.7	13

#	Article	IF	Citations
91	Adjuvant vancomycin for antibiotic prophylaxis and risk of Clostridium difficile infection after coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 472-478.	0.8	13
92	Missing laboratory results data in electronic health databases: implications for monitoring diabetes risk. Journal of Comparative Effectiveness Research, 2017, 6, 25-32.	1.4	13
93	Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices. Clinical Pharmacology and Therapeutics, 2018, 103, 1093-1099.	4.7	13
94	Transparent Reporting on Research Using Unstructured Electronic Health Record Data to Generate â€˜Real Worldâ€™ Evidence of Comparative Effectiveness and Safety. Drug Safety, 2019, 42, 1297-1309.	3.2	13
95	Using Healthcare Databases to Refine Understanding of Exploratory Associations Between Drugs and Progression of Openâ€Angle Glaucoma. Clinical Pharmacology and Therapeutics, 2019, 106, 874-883.	4.7	13
96	Early Steps in the Development of a Claims-Based Targeted Healthcare Safety Monitoring System and Application to Three Empirical Examples. Drug Safety, 2012, 35, 407-416.	3.2	12
97	Evaluation of Switching Patterns in FDAâ€™s Sentinel System: A New Tool to Assess Generic Drugs. Drug Safety, 2018, 41, 1313-1323.	3.2	12
98	Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 113-121.	0.9	12
99	Finding Meaningful Patterns in Adverse Drug Event Reports. JAMA Internal Medicine, 2014, 174, 1934.	5.1	11
100	Common Models, Different Approaches. Drug Safety, 2015, 38, 683-686.	3.2	11
101	Comparison of Calipers for Matching on the Disease Risk Score. American Journal of Epidemiology, 2016, 183, 937-948.	3.4	11
102	Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis. Drug Safety, 2017, 40, 923-932.	3.2	11
103	Reuse of data sources to evaluate drug safety signals: When is it appropriate?. Pharmacoepidemiology and Drug Safety, 2018, 27, 567-569.	1.9	11
104	Use of rheumatology-specific patient navigators to understand and reduce barriers to medication adherence: Analysis of qualitative findings. PLoS ONE, 2018, 13, e0200886.	2.5	11
105	Comparison of a new 3-item self-reported measure of adherence to medication with pharmacy claims data in patients with cardiometabolic disease. American Heart Journal, 2020, 228, 36-43.	2.7	11
106	Quality of Care Measures for Migraine: A Comprehensive Review. Disease Management: DM, 2007, 10, 138-146.	1.0	10
107	An Eventâ€Based Approach for Comparing the Performance of Methods for Prospective Medical Product Monitoring. Pharmacoepidemiology and Drug Safety, 2012, 21, 631-639.	1.9	10
108	Selective Serotonin Reuptake Inhibitor Use and Perioperative Bleeding and Mortality in Patients Undergoing Coronary Artery Bypass Grafting: A Cohort Study. Drug Safety, 2015, 38, 1075-1082.	3.2	10

#	Article	IF	Citations
109	A Review of Disease Risk Scores and Their Application in Pharmacoepidemiology. Current Epidemiology Reports, 2016, 3, 277-284.	2.4	10
110	Understanding Breast Cancer Knowledge and Barriers to Treatment Adherence: A Qualitative Study Among Breast Cancer Survivors. BioResearch Open Access, 2017, 6, 159-168.	2.6	10
111	Safety assessment of niacin in the US Food and Drug Administration's miniâ€sentinel system. Pharmacoepidemiology and Drug Safety, 2018, 27, 30-37.	1.9	10
112	Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use. Clinical Pharmacology and Therapeutics, 2019, 105, 1513-1521.	4.7	10
113	Quantifying bias reduction with fixedâ€duration versus allâ€available covariate assessment periods. Pharmacoepidemiology and Drug Safety, 2019, 28, 665-670.	1.9	10
114	Bias in caseâ€crossover studies of medications due to persistent use: A simulation study. Pharmacoepidemiology and Drug Safety, 2020, 29, 1079-1085.	1.9	10
115	Active Surveillance of Follow-on Biologics: A Prescription for Uptake. Drug Safety, 2017, 40, 105-108.	3.2	9
116	Identifying signals of interest when screening for drugâ€outcome associations in health care data. British Journal of Clinical Pharmacology, 2018, 84, 1865-1867.	2.4	9
117	Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome. Pharmacoepidemiology and Drug Safety, 2018, 27, 1361-1370.	1.9	9
118	Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States. JAMA - Journal of the American Medical Association, 2020, 323, 87.	7.4	9
119	Trends in Utilization of Prescribed Controlled Substances in US Commercially Insured Adults, 2004-2019. JAMA Internal Medicine, 2020, 180, 1006.	5.1	9
120	Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes. Drugs, 2015, 75, 633-650.	10.9	8
121	Methods for using clinical laboratory test results as baseline confounders in multiâ€site observational database studies when missing data are expected. Pharmacoepidemiology and Drug Safety, 2016, 25, 798-814.	1.9	8
122	Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process. Pharmacoepidemiology and Drug Safety, 2017, 26, 694-701.	1.9	8
123	Extension of Disease Risk Scoreâ€"Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation. American Journal of Epidemiology, 2018, 187, 2439-2448.	3.4	8
124	A Survey of Patientsâ€™ Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications. Journal of General Internal Medicine, 2019, 34, 420-428.	2.6	8
125	Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. Pharmacoepidemiology and Drug Safety, 2020, 29, 757-769.	1.9	8
126	A General Propensity Score for Signal Identification Using Tree-Based Scan Statistics. American Journal of Epidemiology, 2021, 190, 1424-1433.	3.4	8

#	Article	IF	Citations
127	Trends in Medicare Part D Inhaler Spending: 2012–2018. Annals of the American Thoracic Society, 2021, 18, 548-550.	3.2	8
128	Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017. Value in Health, 2021, 24, 804-811.	0.3	8
129	Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval. PLoS ONE, 2016, 11, e0163339.	2.5	8
130	Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness. Drug Safety, 2015, 38, 849-853.	3.2	7
131	Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence. Drugs, 2017, 77, 427-433.	10.9	7
132	Synergies From Integrating Randomized Controlled Trials and Real‐World Data Analyses. Clinical Pharmacology and Therapeutics, 2017, 102, 914-916.	4.7	7
133	Sequential surveillance for drug safety in a regulatory environment. Pharmacoepidemiology and Drug Safety, 2018, 27, 707-712.	1.9	7
134	Can Patient Navigators Improve Adherence to Disease‐Modifying Antirheumatic Drugs? Quantitative Findings From a Six‐Month Single‐Arm Pilot Intervention. Arthritis Care and Research, 2018, 70, 1400-1405.	3.4	7
135	Differences in characteristics of Medicare patients treated by ophthalmologists and optometrists. PLoS ONE, 2020, 15, e0227783.	2.5	7
136	A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs. Drug Safety, 2021, 44, 743-751.	3.2	7
137	Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors. JAMA Network Open, 2022, 5, e220194.	5.9	7
138	Cigarette Purchases at Pharmacies by Patients at High Risk of Smoking-Related Illness. JAMA Internal Medicine, 2014, 174, 2031.	5.1	6
139	Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database. Pharmacoepidemiology and Drug Safety, 2016, 25, 1023-1032.	1.9	6
140	Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics. Diabetes Research and Clinical Practice, 2016, 115, 60-67.	2.8	6
141	The Potential Return on Public Investment in Detecting Adverse Drug Effects. Medical Care, 2017, 55, 545-551.	2.4	6
142	Evidence of potential bias in a comparison of $β$ blockers and calcium channel blockers in patients with chronic obstructive pulmonary disease and acute coronary syndrome: results of a multinational study. BMJ Open, 2017, 7, e012997.	1.9	6
143	Cancer drug shortages: Awareness and perspectives from a representative sample of the US population. Cancer, 2018, 124, 2205-2211.	4.1	6
144	Evaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drug‐outcome associations: The case of clindamycin and *Clostridium difficile* infection. Pharmacoepidemiology and Drug Safety, 2018, 27, 731-739.	1.9	6

#	Article	IF	Citations
145	Assessing the impact of the new ICD–10–CM coding system on pharmacoepidemiologic studies—An application to the known association between angiotensin–converting enzyme inhibitors and angioedema. Pharmacoepidemiology and Drug Safety, 2018, 27, 829-838.	1.9	6
146	Defining Exposure in Observational Studies Comparing Outcomes of Treatment Discontinuation. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004684.	2.2	6
147	General Population vs. Patient Preferences in Anticoagulant Therapy: A Discrete Choice Experiment. Patient, 2019, 12, 235-246.	2.7	6
148	Comparison of Different Case-Crossover Variants in Handling Exposure-Time Trend or Persistent-User Bias: Using Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure as an Example. Value in Health, 2020, 23, 217-226.	0.3	6
149	Consequences of Depletion of Susceptibles for Hazard Ratio Estimators Based on Propensity Scores. Epidemiology, 2020, 31, 806-814.	2.7	6
150	Risk of sudden cardiac arrest and ventricular arrhythmia with sulfonylureas: An experience with conceptual replication in two independent populations. Scientific Reports, 2020, 10, 10070.	3.3	6
151	Empirical assessment of case–based methods for drug safety alert identification in the French National Healthcare System database (SNDS): Methodology of the ALCAPONE project. Pharmacoepidemiology and Drug Safety, 2020, 29, 993-1000.	1.9	6
152	Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications. Value in Health, 2020, 23, 434-440.	0.3	6
153	Restrictive Reimbursement Policies: Bias Implications for Claims-Based Drug Safety Studies. Drug Safety, 2014, 37, 771-776.	3.2	5
154	Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence. Pharmacoepidemiology and Drug Safety, 2016, 25, 944-952.	1.9	5
155	Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System. Drug Safety, 2019, 42, 85-93.	3.2	5
156	The Devil's in the details: Reports on reproducibility in pharmacoepidemiologic studies. Pharmacoepidemiology and Drug Safety, 2019, 28, 671-679.	1.9	5
157	Empirical assessment of case–based methods for identification of drugs associated with upper gastrointestinal bleeding in the French National Healthcare System database (<scp>SNDS</scp>). Pharmacoepidemiology and Drug Safety, 2020, 29, 890-903.	1.9	5
158	Potentially disruptive life events: what are the immediate impacts on chronic disease management? A case-crossover analysis. BMJ Open, 2016, 6, e010958.	1.9	4
159	Evaluating the use of bootstrapping in cohort studies conducted with 1:1 propensity score matching—A plasmode simulation study. Pharmacoepidemiology and Drug Safety, 2019, 28, 879-886.	1.9	4
160	Screening Medications for Association with Progression to Wet Age-Related Macular Degeneration. Ophthalmology, 2021, 128, 248-255.	5.2	4
161	Drug–Drug Interaction Surveillance Study: Comparing Self–Controlled Designs in Five Empirical Examples in Real–World Data. Clinical Pharmacology and Therapeutics, 2021, 109, 1353-1360.	4.7	4
162	Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program. Drug Safety, 2021, 44, 327-335.	3.2	4

#	Article	IF	Citations
163	Assessing Quality of Care for Migraineurs: A Model Health Plan Measurement Set. Population Health Management, 2008, 11, 203-208.	1.7	3
164	Comment on 'Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership'. Statistics in Medicine, 2013, 32, 1073-1074.	1.6	3
165	Prospective Benefit-Risk Monitoring of New Drugs for Rapid Assessment of Net Favorability in Electronic Health Care Data. Value in Health, 2015, 18, 1063-1069.	0.3	3
166	Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation Study. Value in Health, 2015, 18, 1057-1062.	0.3	3
167	New-user designs with conditional propensity scores: a unified complement to the traditional active comparator new-user approach. Pharmacoepidemiology and Drug Safety, 2017, 26, 469-471.	1.9	3
168	Simulation for Predicting Effectiveness and Safety of New Cardiovascular Drugs in Routine Care Populations. Clinical Pharmacology and Therapeutics, 2018, 104, 1008-1015.	4.7	3
169	Role of Authorized Generics in Postapproval Surveillance of Generic Drug Products. Clinical Pharmacology and Therapeutics, 2019, 105, 313-315.	4.7	3
170	Evaluation of Use of Technologies to Facilitate Medical Chart Review. Drug Safety, 2019, 42, 1071-1080.	3.2	3
171	Using the Case-Crossover Design to Assess Short-Term Risks of Bleeding and Arterial Thromboembolism After Switching Between Oral Anticoagulants in a Population-Based Cohort of Patients With Atrial Fibrillation. American Journal of Epidemiology, 2020, 189, 1467-1477.	3.4	3
172	Empirical assessment of case-based methods for identification of drugs associated with acute liver injury in the French National Healthcare System database (<scp>SNDS</scp>). Pharmacoepidemiology and Drug Safety, 2021, 30, 320-333.	1.9	3
173	SMART Designs in Observational Studies of Opioid Therapy Duration. Journal of General Internal Medicine, 2014, 29, 429-431.	2.6	2
174	Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. Pharmacoepidemiology and Drug Safety, 2018, 27, 383-390.	1.9	2
175	Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study. Journal of Comparative Effectiveness Research, 2018, 7, 57-66.	1.4	2
176	Diagnosis-based cohort augmentation using laboratory results data: The case of chronic kidney disease. Pharmacoepidemiology and Drug Safety, 2018, 27, 872-877.	1.9	2
177	Comparative Outcomes of Treatment Initiation With Brand vs. Generic Warfarin in Older Patients. Clinical Pharmacology and Therapeutics, 2020, 107, 1334-1342.	4.7	2
178	Association of California's Prescription Drug Coupon Ban With Generic Drug Use. JAMA - Journal of the American Medical Association, 2021, 325, 2399.	7.4	2
179	Preferences for and Experiences With Pill Appearance Changes: National Surveys of Patients and Pharmacists. American Journal of Managed Care, 2020, 26, 340-347.	1.1	2
180	Comment: Generic Substitution of Antiepileptic Drugs: A Systematic Review of Prospective and Retrospective Studies. Annals of Pharmacotherapy, 2012, 46, 303-304.	1.9	1

#	Article	IF	Citations
181	On analyzing therapeutic ineffectiveness reports. Pharmacoepidemiology and Drug Safety, 2013, 22, 207-208.	1.9	1
182	Balancing benefits and harms: privacy protection policies. Pharmacoepidemiology and Drug Safety, 2016, 25, 969-971.	1.9	1
183	Time for integrating clinical, lifestyle and molecular data to predict drug responses â€" Authors' reply. EBioMedicine, 2016, 7, 11.	6.1	1
184	Strength of evidence for labeled dosing recommendations in renal impairment. Clinical Trials, 2017, 14, 219-221.	1.6	1
185	What Does a Cancer Diagnosis Mean? Public Expectations in a Shifting Therapeutic Environment. Journal of Oncology Practice, 2018, 14, 139-140.	2.5	1
186	Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data. Journal of Comparative Effectiveness Research, 2018, 7, 1073-1082.	1.4	1
187	Impact of a Metoprolol Extended Release Shortage on Post-Myocardial Infarction Î²-Blocker Utilization, Adherence, and Rehospitalization. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004096.	2.2	1
188	Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study. Drug Safety, 2019, 42, 1355-1363.	3.2	1
189	Errors in Exclusion of Data and Reported Trends of Prescriptions in Study of Opioid Prescriptions Dispensed to Children and Adolescents. JAMA Pediatrics, 2019, 173, 697.	6.2	1
190	Response to â€œThe Selfâ€Controlled Case Series Design as a Viable Alternative to Studying Clinically Relevant Drug Interactionsâ€. Clinical Pharmacology and Therapeutics, 2020, 107, 323-323.	4.7	1
191	Exact sequential analysis for multiple weighted binomial end points. Statistics in Medicine, 2020, 39, 340-351.	1.6	1
192	Improving measurement of binary covariates in claims data: A simulation study. Pharmacoepidemiology and Drug Safety, 2020, 29, 1093-1100.	1.9	1
193	COPD EXACERBATIONS AND PNEUMONIA HOSPITALIZATIONS IN NEW USERS OF COMBINATION MAINTENANCE INHALERS: A COMPARATIVE EFFECTIVENESS AND SAFETY STUDY. Chest, 2021, 160, A1795.	0.8	1
194	Health Advisories and Patterns of Patient Monitoring Among New Users of Antidepressant Medications. Journal of Clinical Psychopharmacology, 2009, 29, 590-594.	1.4	0
195	Developing alerting thresholds for prospective drug safety monitoring. Pharmacoepidemiology and Drug Safety, 2016, 25, 755-762.	1.9	0
196	Prescription Trendsâ€"Brand-Name Drugs vs Genericâ€"Reply. JAMA Internal Medicine, 2016, 176, 1574.	5.1	0
197	The Role of Hemoglobin Laboratory Test Results for the Detection of Upper Gastrointestinal Bleeding Outcomes Resulting from the Use of Medications in Observational Studies. Drug Safety, 2017, 40, 91-100.	3.2	0
198	Trends and Patterns of Corticosteroid Use During Coronary Artery Bypass Grafting Surgery in the United States. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 226-236.	2.0	0

#	ARTICLE	IF	CITATIONS
199	Concern still warranted: medication burden and persistence with lipid-lowering drugs. American Journal of Managed Care, 2009, 15, 74-5.	1.1	0
200	Type of Oral Anticoagulant and Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for VTEâ€"Reply. JAMA - Journal of the American Medical Association, 2022, 328, 79.	7.4	0